Healthcare Services

Conjunctivitis Treatment Industry Expansion Forecast Showing Market Size of $6.13 Billion by 2030 at 4.7% CAGR

March 31, 2026March 31, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Conjunctivitis Treatment Market During 2026–2030?

The conjunctivitis treatment market size has experienced consistent expansion in recent years. It is anticipated to increase from $4.89 billion in 2025 to $5.1 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.3%. The market’s historical growth can be attributed to the high incidence of eye infections, widespread bacterial and viral exposure, limited access to ophthalmology care, reliance on topical antibiotics, and the prevalence of seasonal allergies.

The conjunctivitis treatment market is projected to experience steady expansion in the coming years.

The market size is expected to reach $6.13 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.7%.

This anticipated growth during the forecast period is driven by factors such as increasing awareness of eye hygiene, rising self-medication trends, the growth of OTC ophthalmic products, expanding urban populations, and improved access to eye care.

Key trends for the forecast period include a rising demand for preservative-free eye drops, an increased use of combination drug formulations, a growth in over-the-counter treatment adoption, a focus on faster symptom relief therapies, and the expansion of homecare-based treatment options.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12051&type=smp

Which Major Factors Are Driving The Expansion Of The Conjunctivitis Treatment Market?

The conjunctivitis treatment market is expected to see growth propelled by the increasing geriatric population. This demographic, comprising elderly or senior citizens, is more susceptible to various eye conditions like conjunctivitis. Factors contributing to this heightened susceptibility include weakened immune systems, pre-existing medical conditions, and age-related changes in eye health, making older individuals more prone to infections. For illustration, according to the UK Parliament’s House of Commons Library, a UK-based government administration, in July 2024, there were 12.7 million individuals aged 65 or older in the UK in 2022, which accounted for 19% of the total population. This number is projected to climb to 22.1 million by 2072, making up 27% of the population. Thus, the expanding geriatric population is a key driver for the conjunctivitis treatment market’s growth.

How Are The Various Segments Of The Conjunctivitis Treatment Market Categorized?

The conjunctivitis treatment market covered in this report is segmented –

1) By Drug Class: Antibiotics, Antiviral, Anti-Allergic, Artificial Tears

2) By Disease Type: Allergic Conjunctivitis, Bacterial Conjunctivitis, Viral Conjunctivitis

3) By Route Of Administration: Oral, Topical

4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Antibiotics Conjunctivitis Treatment: Topical Antibiotic Drops, Ointment-Based Antibiotics, Combination Antibiotic Formulations, Preservative-Free Antibiotic Solutions

2) By Antiviral Conjunctivitis Treatment: Topical Antiviral Drops, Oral Antiviral Medications, Combination Antiviral Formulations, Ophthalmic Antiviral Ointments

3) By Anti-Allergic Conjunctivitis Treatment: Antihistamine Eye Drops, Mast Cell Stabilizer Drops, Combination Anti-Allergic Formulations, Preservative-Free Anti-Allergic Solutions

4) By Artificial Tears Conjunctivitis Treatment: Lubricating Eye Drops, Gel-Based Artificial Tears, Preservative-Free Artificial Tears, Combination Moisturizing Formulations

How Are Trends Shaping The Direction Of The Conjunctivitis Treatment Market?

Companies engaged in the conjunctivitis treatment market are concentrating on developing and launching products, such as ophthalmic solutions, to maintain their market presence. For example, in July 2023, Harrow, Inc., a US-based company specializing in ophthalmic healthcare, introduced five innovative ophthalmic products in the United States. These include FLAREX (fluorometholone acetate ophthalmic suspension) 0.1%, which addresses steroid-responsive inflammatory conditions of the eye; NATACYN (natamycin ophthalmic suspension) 5%, identified as the sole FDA-approved topical ophthalmic antifungal medication for fungal blepharitis, conjunctivitis, and keratitis; TOBRADEX ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05%, formulated for inflammatory ocular conditions necessitating a corticosteroid and presenting a risk of bacterial ocular infection; VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a patented ‘orphan-designated product’ designed for treating vernal keratoconjunctivitis in both children and adults; and ZERVIATE (cetirizine ophthalmic solution) 0.24%, which targets ocular itching associated with allergic conjunctivitis. This extensive product introduction demonstrates Harrow, Inc.’s dedication to offering diverse and targeted remedies for various ophthalmic conditions.

Which Major Firms Influence Developments In The Conjunctivitis Treatment Market?

Major companies operating in the conjunctivitis treatment market are Alcon Laboratories Inc., Santen Pharmaceuticals Co. Ltd, Eyevance Pharmaceuticals LLC, Johnson and Johnson, Bausch Health Companies Inc., Cipla Inc., Dr Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Lupin Limited, Alembic Pharmaceuticals Ltd., Akorn Inc., Micro Labs Ltd., Ocular Therapeutics Inc., GlaxoSmithKline plc, Merck & Co Inc, Vanda Pharmaceuticals, Aldeyra Therapeutics, Allakos Inc, Regeneron Pharmaceuticals, Marinomed Biotech AG, Eleusis Holdings Ltd, IACTA Pharmaceuticals, Nanomerics, OKYO Pharma, Stuart Therapeutics

Read the full conjunctivitis treatment market report here:

https://www.thebusinessresearchcompany.com/report/conjunctivitis-treatment-global-market-report

Which Region Currently Holds The Largest Share Of The Conjunctivitis Treatment Market?

North America was the largest region in the conjunctivitis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the conjunctivitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Conjunctivitis Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12051&type=smp

Browse Through More Reports Similar to the Global Conjunctivitis Treatment Market 2026, By The Business Research Company

Congestive Heart Failure Treatment Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/congestive-heart-failure-treatment-devices-global-market-report

Congenital Heart Disease Chd Global Market Report

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Structural Heart Global Market Report

https://www.thebusinessresearchcompany.com/report/structural-heart-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795